137 related articles for article (PubMed ID: 38340329)
21. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
22. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
23. Silent corticotroph adenomas.
Ben-Shlomo A; Cooper O
Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.
Zhou W; Zhang C; Zhang D; Peng J; Ma S; Wang X; Guan X; Li P; Li D; Jia G; Jia W
J Neurooncol; 2020 Sep; 149(3):473-487. PubMed ID: 33034841
[TBL] [Abstract][Full Text] [Related]
25. β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids.
Gatto F; Feelders RA; van der Pas R; van Koetsveld P; Bruzzone E; Arvigo M; Dogan F; Lamberts S; Ferone D; Hofland L
J Endocrinol; 2020 Apr; 245(1):101-113. PubMed ID: 32027601
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of silent corticotroph adenomas.
Alahmadi H; Lee D; Wilson JR; Hayhurst C; Mete O; Gentili F; Asa SL; Zadeh G
Acta Neurochir (Wien); 2012 Aug; 154(8):1493-8. PubMed ID: 22619024
[TBL] [Abstract][Full Text] [Related]
27. [Pathology and pathogenesis of pituitary corticotroph adenoma].
Trouillas J
Neurochirurgie; 2002 May; 48(2-3 Pt 2):149-62. PubMed ID: 12058122
[TBL] [Abstract][Full Text] [Related]
28. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI.
Amano T; Masumoto T; Watanabe D; Hoshiai S; Mori K; Sakamoto N; Kino H; Akutsu H; Nakajima T
Jpn J Radiol; 2023 Sep; 41(9):938-946. PubMed ID: 37027094
[TBL] [Abstract][Full Text] [Related]
30. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
31. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
32. Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.
Lim JS; Lee MK; Choi E; Hong N; Il Jee S; Kim SH; Lee EJ
Endocrine; 2019 Apr; 64(1):147-156. PubMed ID: 30474823
[TBL] [Abstract][Full Text] [Related]
33. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
34. Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study.
Di Meo A; Rotondo F; Kovacs K; Cusimano MD; Syro LV; Di Ieva A; Diamandis EP; Yousef GM
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):433-7. PubMed ID: 25517869
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
36. ACTH adenomas transforming their clinical expression: report of 5 cases.
Zoli M; Faustini-Fustini M; Mazzatenta D; Marucci G; De Carlo E; Bacci A; Pasquini E; Lanzino G; Frank G
Neurosurg Focus; 2015 Feb; 38(2):E15. PubMed ID: 25639317
[TBL] [Abstract][Full Text] [Related]
37. Identifying Glucocorticoid Insufficiency in Silent Corticotroph Adenoma with Elevated Adrenocorticotropic Hormone.
Schlegel A
Lab Med; 2022 Jan; 53(1):91-94. PubMed ID: 34270735
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.
Vuong HG; Dunn IF
Endocrine; 2023 Dec; 82(3):527-535. PubMed ID: 37462809
[TBL] [Abstract][Full Text] [Related]
39. Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma.
Karavitaki N; Scheithauer BW; Watt J; Ansorge O; Moschopoulos M; Llaguno AV; Wass JA
Pituitary; 2008; 11(3):317-23. PubMed ID: 17917812
[TBL] [Abstract][Full Text] [Related]
40. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O; Boldt HB; Engström BE; Andersen MS; Baussart B; Bengtsson D; Berinder K; Ekman B; Feldt-Rasmussen U; Höybye C; Jørgensen JOL; Kolnes AJ; Korbonits M; Rasmussen ÅK; Lindsay JR; Loughrey PB; Maiter D; Manojlovic-Gacic E; Pahnke J; Poliani PL; Popovic V; Ragnarsson O; Schalin-Jäntti C; Scheie D; Tóth M; Villa C; Wirenfeldt M; Kunicki J; Burman P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1183-1194. PubMed ID: 33106857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
